Alteration of MMP-2 and -14 expression by imatinib in HPV-positive and -negative squamous cell carcinoma

Oncology Reports

Volumn 28, Issue 1, 2012, Pages 172-178

  Faber, Anne ^a   Sauter, Alexander ^a   Hoedt, Sarah ^a   Hoermann, Karl ^a   Erben, Philipp ^a   Hofheinz, Ralf Dieter ^a   Sommer, Ulrich ^a   Stern Straeter, Jens ^a   Schultz, David Johannes ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Head and neck squamous cell carcinoma; Human papilloma virus; Imatinib; MMP 14; MMP 2; Protein tyrosine kinase

Indexed keywords

CARBOPLATIN; GELATINASE A; IMATINIB; MATRIX METALLOPROTEINASE 14; TYROSINE KINASE RECEPTOR;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CONCENTRATION RESPONSE; CONTROLLED STUDY; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN CELL; INCUBATION TIME; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION; RECEPTOR BLOCKING; SIGNAL TRANSDUCTION; WART VIRUS;

ANTINEOPLASTIC AGENTS; CARBOPLATIN; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; GENE EXPRESSION; HEAD AND NECK NEOPLASMS; HUMAN PAPILLOMAVIRUS 16; HUMANS; MATRIX METALLOPROTEINASE 14; MATRIX METALLOPROTEINASE 2; PAPILLOMAVIRUS INFECTIONS; PIPERAZINES; PYRIMIDINES;

EID: 84861549468     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2012.1766     Document Type: Article

References (57)

1. Edwards BK, Howe HL, Ries LA, et al: Annual report to the nation on the status of cancer, 1973-1999, featuring implications of age and aging on U.S. cancer burden. Cancer 94: 2766-2792, 2002. (Pubitemid 34478095)
2. Vokes EE, Weichselbaum RR, Lippman SM and Hong WK: Head and neck cancer. N Engl J Med 328: 184-194, 1993.
3. Dimery IW and Hong WK: Overview of combined modality therapies for head and neck cancer. J Natl Cancer Inst 85: 95-111, 1993. (Pubitemid 23028714)
4. Gallo O, Chiarelli I, Boddi V, Bocciolini C, Bruschini L and Porfirio B: Cumulative prognostic value of p53 mutations and bcl-2 protein expression in head-and-neck cancer treated by radiotherapy. Int J Cancer 84: 573-579, 1999.
5. Grandis JR, Chakraborty A, Zeng Q, Melhem MF and Tweardy DJ: Downmodulation of TGF-α protein expression with antisense oligonucleotides inhibits proliferation of head and neck squamous carcinoma but not normal mucosal epithelial cells. J Cell Biochem 69: 55-62, 1998. (Pubitemid 28099922)
6. Pignataro L, Pruneri G, Carboni N, et al: Clinical relevance of cyclin D1 protein overexpression in laryngeal squamous cell carcinoma. J Clin Oncol 16: 3069-3077, 1998. (Pubitemid 28417428)
7. Riechelmann H, Sauter A, Golze W, et al: Phase I trial with the CD44v6-targeting immunoconjugate bivatuzumab mertansine in head and neck squamous cell carcinoma. Oral Oncol 44: 823-829, 2008.
8. Sauter A, Kloft C, Gronau S, et al: Pharmacokinetics, immunogenicity and safety of bivatuzumab mertansine, a novel CD44v6-targeting immunoconjugate, in patients with squamous cell carcinoma of the head and neck. Int J Oncol 30: 927-935, 2007.
9. Rijkaart DC, Berkhof J, Rozendaal L, et al: Human papilloma-virus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial. Lancet Oncol 13: 78-88, 2012.
10. Mendoza N, Hernandez PO and Tyring SK: HPV vaccine update: new indications and controversies. Skin Therapy Lett 16: 1-3, 2011.
11. Antonsson A, Spurr TP, Chen AC, et al: High prevalence of human papillomaviruses in fresh frozen breast cancer samples. J Med Virol 83: 2157-2163, 2011.
12. Shiboski CH, Schmidt BL and Jordan RC: Tongue and tonsil carcinoma: increasing trends in the U.S. population ages 20-44 years. Cancer 103: 1843-1849, 2005. (Pubitemid 40563256)
13. Gillison ML, Koch WM, Capone RB, et al: Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst 92: 709-720. 2000. (Pubitemid 30365531)
14. Nasman A, Attner P, Hammarstedt L, et al: Incidence of human papillomavirus (HPV) positive tonsillar carcinoma in Stockholm, Sweden: an epidemic of viral-induced carcinoma? Int J Cancer 125: 362-366, 2009.
15. Attner P, Du J, Nasman A, et al: The role of human papilloma-virus in the increased incidence of base of tongue cancer. Int J Cancer 126: 2879-2884, 2010.
16. Romanitan M, Nasman A, Ramqvist T, et al: Human papilloma-virus frequency in oral and oropharyngeal cancer in Greece. Anticancer Res 28: 2077-2080, 2008.
17. Chaturvedi AK, Engels EA, Pfeiffer RM, et al: Human papilloma-virus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol 29: 4294-4301, 2011.
18. Kreimer AR, Clifford GM, Boyle P and Franceschi S: Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomarkers Prev 14: 467-475, 2005. (Pubitemid 40270113)
19. Kreimer AR and Chaturvedi AK: HPV-associated oropharyngeal cancers - are they preventable? Cancer Prev Res 4: 1346-1349, 2011.
20. Koch WM, Lango M, Sewell D, Zahurak M and Sidransky D: Head and neck cancer in non-smokers: a distinct clinical and molecular entity. Laryngoscope 109: 1544-1551, 1999. (Pubitemid 29477216)
21. Crosby RA, Diclemente RJ, Salazar LF, Nash R, Younge S and Head S: Human papillomavirus vaccine intention among college men: what's oral sex got to do with it? J Am Coll Health 60: 8-12, 2012.
22. Rautava J, Kuuskoski J, Syrjanen K, Grenman R and Syrjanen S: HPV genotypes and their prognostic significance in head and neck squamous cell carcinomas. J Clin Virol 53: 116-120, 2012.
23. Blume-Jensen P and Hunter T: Oncogenic kinase signalling. Nature 411: 355-365, 2001. (Pubitemid 32467045)
24. Ford AC and Grandis JR: Targeting epidermal growth factor receptor in head and neck cancer. Head Neck 25: 67-73, 2003. (Pubitemid 36005333)
25. Lydon NB and Druker BJ: Lessons learned from the development of imatinib. Leuk Res 28 (Suppl 1): S29-S38, 2004. (Pubitemid 38251496)
26. Buchdunger E, Zimmermann J, Mett H, et al: Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res 56: 100-104, 1996.
27. Druker BJ, Tamura S, Buchdunger E, et al: Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 2: 561-566, 1996.
28. Bran B, Bran G, Hormann K and Riedel F: The platelet-derived growth factor receptor as a target for vascular endothelial growth factor-mediated anti-angiogenetic therapy in head and neck cancer. Int J Oncol 34: 255-261, 2009.
29. O-Charoenrat P, Rhys-Evans PH and Eccles SA: Expression of matrix metalloproteinases and their inhibitors correlates with invasion and metastasis in squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg 127: 813-820, 2001.
30. Okada A, Bellocq JP, Rouyer N, et al: Membrane-type matrix metalloproteinase (MT-MMP) gene is expressed in stromal cells of human colon, breast, and head and neck carcinomas. Proc Natl Acad Sci USA 92: 2730-2734, 1995.
31. Zarrabi K, Dufour A, Li J, et al: Inhibition of matrix metalloproteinase- 14 (MMP-14)-mediated cancer cell migration. J Biol Chem 286: 33167-33177, 2011.
32. Sabeh F, Li XY, Saunders TL, Rowe RG and Weiss SJ: Secreted versus membrane-anchored collagenases: relative roles in fibroblast-dependent collagenolysis and invasion. J Biol Chem 284: 23001-23011, 2009.
33. Schultz JD, Rotunno S, Erben P, et al: Down-regulation of MMP-2 expression due to inhibition of receptor tyrosine kinases by imatinib and carboplatin in HNSCC. Oncol Rep 25: 1145-1151, 2011.
34. Druker BJ and Lydon NB: Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J Clin Invest 105: 3-7, 2000. (Pubitemid 30036380)
35. Heinrich MC, Griffith DJ, Druker BJ, Wait CL, Ott KA and Zigler AJ: Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood 96: 925-932, 2000. (Pubitemid 30618049)
36. Popow-Wozniak A, Wozniakowska A, Kaczmarek L, Malicka-Blaszkiewicz M and Nowak D: Apoptotic effect of imatinib on human colon adenocarcinoma cells: influence on actin cyto-skeleton organization and cell migration. Eur J Pharmacol 667: 66-73, 2011.
37. Tsao AS, Liu S, Fujimoto J, et al: Phase II trials of imatinib mesylate and docetaxel in patients with metastatic non-small cell lung cancer and head and neck squamous cell carcinoma. J Thorac Oncol 6: 2104-2111, 2011.
38. Hirota S, Isozaki K, Moriyama Y, et al: Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 279: 577-580, 1998. (Pubitemid 28067289)
39. Gorogh T, Beier UH, Baumken J, et al: Metalloproteinases and their inhibitors: influence on tumor invasiveness and metastasis formation in head and neck squamous cell carcinomas. Head Neck 28: 31-39, 2006. (Pubitemid 43099633)
40. Moscatelli D and Rifkin DB: Membrane and matrix localization of proteinases: a common theme in tumor cell invasion and angiogenesis. Biochim Biophys Acta 948: 67-85, 1988.
41. Liotta LA and Stetler-Stevenson WG: Tumor invasion and metastasis: an imbalance of positive and negative regulation. Cancer Res 51: S5054-S5059, 1991.
42. Libra M, Scalisi A, Vella N, et al: Uterine cervical carcinoma: role of matrix metalloproteinases (review). Int J Oncol 34: 897-903, 2009.
43. Gondivkar SM, Parikh RV, Gadbail AR, et al: Involvement of viral factors with head and neck cancers. Oral Oncol: Nov 9, 2011 (Epub ahead of print).
44. Fernandes T, de Angelo-Andrade LA, Morais SS, et al: Stromal cells play a role in cervical cancer progression mediated by MMP-2 protein. Eur J Gynaecol Oncol 29: 341-344, 2008.
45. Giannelli G, Falk-Marzillier J, Schiraldi O, Stetler-Stevenson WG and Quaranta V: Induction of cell migration by matrix metalloprotease- 2 cleavage of laminin-5. Science 277: 225-228, 1997. (Pubitemid 27446075)
46. Sheu BC, Lien HC, Ho HN, et al: Increased expression and activation of gelatinolytic matrix metalloproteinases is associated with the progression and recurrence of human cervical cancer. Cancer Res 63: 6537-6542, 2003.
47. Yang SF, Wang PH, Lin LY, et al: A significant elevation of plasma level of matrix metalloproteinase-9 in patients with high-grade intraepithelial neoplasia and early squamous cell carcinoma of the uterine cervix. Reprod Sci 14: 710-718, 2007.
48. Seiki M: Membrane-type 1 matrix metalloproteinase: a key enzyme for tumor invasion. Cancer Lett 194: 1-11, 2003.
49. Mook OR, Frederiks WM and van Noorden CJ: The role of gelatinases in colorectal cancer progression and metastasis. Biochim Biophys Acta 1705: 69-89, 2004. (Pubitemid 39592897)
50. Shimizu M, Minakuchi K, Tsuda A, et al: Role of stem cell factor and c-kit signaling in regulation of fetal intestinal epithelial cell adhesion to fibronectin. Exp Cell Res 266: 311-322, 2001. (Pubitemid 32579236)
51. Risinger GM Jr, Hunt TS, Updike DL, Bullen EC and Howard EW: Matrix metalloproteinase-2 expression by vascular smooth muscle cells is mediated by both stimulatory and inhibitory signals in response to growth factors. J Biol Chem 281: 25915-25925, 2006. (Pubitemid 44401797)
52. Hanzawa M, Shindoh M, Higashino F, et al: Hepatocyte growth factor upregulates E1AF that induces oral squamous cell carcinoma cell invasion by activating matrix metalloproteinase genes. Carcinogenesis 21: 1079-1085, 2000. (Pubitemid 30389331)
53. Hiscox S and Jiang WG: Hepatocyte growth factor/scatter factor disrupts epithelial tumour cell-cell adhesion: involvement of beta-catenin. Anticancer Res 19: 509-517, 1999. (Pubitemid 29168285)
54. Sauter A, Soulsby H, Hormann K and Naim R: Sulindac sulfone induces a decrease of β-catenin in HNSCC. Anticancer Res 30: 339-343, 2010.
55. Faber A, Barth C, Hormann K, et al: CD44 as a stem cell marker in head and neck squamous cell carcinoma. Oncol Rep 26: 321-326, 2011.
56. Mori H, Tomari T, Koshikawa N, et al: CD44h directs membrane-type 1 matrix metalloproteinase to lamellipodia by associating with its hemopexin-like domain. EMBO J 21: 3949-3959, 2002. (Pubitemid 34857428)
57. Artym VV, Zhang Y, Seillier-Moiseiwitsch F, Yamada KM and Mueller SC: Dynamic interactions of cortactin and membrane type 1 matrix metalloproteinase at invadopodia: defining the stages of invadopodia formation and function. Cancer Res 66: 3034-3043, 2006.